Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 20, 1997

View Archived Issues

Indian investigators prepare novel hypolipidemic agents

Novel LTB4 receptor antagonist described

Schering AG investigates vitamin D derivatives

SKB prepares chimeric leptins

Antitumor heterocyclic compounds from Takeda

Akzo reports peptides for specific tolerance therapy

Zambon discloses ACE/NEP inhibitors

Antifungals from Schering-Plough

PFT inhibitors described by Warner-Lambert

Biorex discloses antiischemic agents

Subtype-selective 5-HT1 antagonists from Pierre Fabre

Anergen reports 1996 financial results

InSite Vision releases 1996 earnings

Interneuron announces first-quarter fiscal 1997 results

Targeted Genetics reports fourth-quarter 1996 financial results

Schering-Plough seeks FDA approval for psoriasis treatment

Xytronyx reports fiscal 1997 third-quarter results

Cortex seeks AMPAkine patent approval

Vasogen to extend clinical trials with VasoCare

New agreement reached for Searle's Maxaquin

AnorMED receives funding for cancer imaging

SIBIA Neurosciences initiates clinical trials of antiparkinsonian product

Immunotherapy cancer vaccine in phase II

Athena Neurosciences and Lilly extend research collaboration

Glaxo Wellcome discovers potent, selective CCK-B/gastrin antagonist

Novel kappa-opioid agonist from Parke-Davis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...